Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).
Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 54 | 2020-07-15 | 2020-12-11 |
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
Pemziviptadil (PB1046) Injection - Pulmonary Arterial Hypertension | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 25 | 2019-04-10 | 2022-02-22 |
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
Pemziviptadil (PB1046) - Pulmonary Arterial Hypertension | Phase 2 | Terminated | PhaseBio Pharmaceuticals Inc. | 35 | 2018-07-15 | 2022-08-23 |
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
PB1046 Subcutaneous Injection - Pulmonary Arterial Hypertension | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 3 | 2017-10-20 | 2019-10-08 |
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
PB1046 Injection, Placebo Injection - Heart Failure | Phase 2 | Completed | PhaseBio Pharmaceuticals Inc. | 29 | 2016-06-01 | 2022-07-14 |
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM
PE0139 Injection, Placebo Injection - Type 2 Diabetes Mellitus | Phase 2 | Completed | PhaseBio Pharmaceuticals Inc. | 37 | 2015-10-01 | 2018-04-10 |
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension
Placebo Single IV (Intravenous) Infusion, Experimental: Single IV Infusion Vasomera (PB1046) - Essential Hypertension | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 20 | 2013-06-01 | 2014-04-10 |
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes Mellitus
PE0139 Injection, Placebo - Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 37 | 2013-04-01 | 2014-10-15 |
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM
50 mg PB1023, 70 mg PB1023, 100 mg PB1023 - Type 2 Diabetes Mellitus | Phase 2 | Completed | PhaseBio Pharmaceuticals Inc. | 593 | 2012-07-01 | 2015-12-07 |
Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus
Single Dose PB1023 - Diabetes Mellitus, Type 2 | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 10 | 2012-02-01 | 2012-10-01 |
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
Vasomera (PB1046), 0.9% Sodium Chloride - Essential Hypertension | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 68 | 2012-01-01 | 2013-01-04 |
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal Function
PB1023 Injection - Diabetes Mellitus, Type 2 | Phase 1 | Completed | PhaseBio Pharmaceuticals Inc. | 16 | 2011-12-01 | 2013-04-15 |
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus
Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl) - Diabetes Mellitus, Type 2 | Phase 1 / Phase 2 | Completed | PhaseBio Pharmaceuticals Inc. | 80 | 2010-11-01 | 2013-05-21 |